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Antimicrobial Activity of Securamines From 
the Bryozoan Securiflustra securifrons
Kine Ø. Hansen1   , Ida K. Ø. Hansen2, Céline S. Richard2   , Marte Jenssen1, 
Jeanette H. Andersen1, and Espen H. Hansen1   
Abstract
Natural products and their derivatives have served as powerful therapeutics against pathogenic microorganisms and are the main-
stay of our currently available treatment options to combat infections. As part of our ongoing search for antimicrobial natural 
products from marine organisms, one fraction prepared from the Arctic marine bryozoan Securiflustra securifrons was found to be 
active against the human pathogenic bacterium Streptococcus agalactiae (gr. B). Chemical investigation of the fraction revealed that it 
contained several variants of the highly modified secondary metabolites known as securamines. The securamines are alkaloids 
sharing a common isoprene- histamine- tryptamine backbone. In this study, we describe the antimicrobial activities of securamine 
C, E, and H – J (4, 5, and 1-3) and the attempt to deconvolute the mode of action of 1.
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The increasing prevalence of  antibiotic resistant pathogens is 
recognized as one of  the most serious global threats to human 
health in the 21st century. Extensive use of  antimicrobials 
together with declining investments into discovery and devel-
opment of  new treatment options to combat pathogens have 
aggravated the problem.1 Novel classes of  antibiotics are 
therefore urgently needed for the future. In the search for new 
antimicrobial agents, nature remains the richest and most ver-
satile source.2,3 In fact, close to 80% of  all marketed anti- 
infective agents originate from a natural source.4
Bryozoans are a phylum of  suspension- feeding mainly 
colonial invertebrates found in aquatic benthic ecosystems 
throughout the world.5 They generally form sessile colonies of  
genetically identical, polymorphic units termed zooids.6,7 These 
colonies are extremely vulnerable to biofouling, predation by 
grazers and pathogenic attacks.8,9 In order to thrive in this hos-
tile environment, bryozoans have developed a chemical defense 
strategy, in which potent secondary metabolites are produced 
to combat these external threats. As a result, bryozoan biomass 
has yielded several structurally diverse bioactive secondary 
metabolites. The best known examples are the bryostatins, iso-
lated from Bugula neritina (Linnaeus, 1758), some of  which are 
under clinical development as an anticancer drug candidate for 
combination therapy10 and neurological disorders.11-13
As part of  our ongoing search for bioactive secondary 
metabolites from marine organisms, the organic extract of  
Securiflustra securifrons (Pallas, 1766) was prepared into eight 
fractions and tested for antibacterial activity. Fraction three was 
found to be active against the pathogenic bacterium Streptococcus 
agalactiae (Gr. B). Previously, fraction five of  the same extract 
was found to be active against a human melanoma cancer cell 
line.14,15 The components found to be responsible for the cyto-
toxicity in this fraction were the hexacyclic alkaloids secur-
amine C (4), E (5), and H – J (1-3) (Figure 1). The structures 
and cytotoxic properties of  1-5 have been reported by our 
group.14 HRMS analysis of  the fraction showing antibacterial 
activity revealed the presence of  securamines. The antimicro-
bial properties of  the securamines have not been previously 
examined. This, coupled with the knowledge that nature has 
provided a wealth of  promising lead structures for antimicro-
bial development,16-18 motivated an investigation into the anti-
microbial potential of  the securamines.
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Results and Discussion
Biomass, Extraction, Fractionation, Compound Isolation, 
and Structure Elucidation
The biomass of  S. securifrons was collected off  the coast of  
Hjelmsøya, freeze dried and subjected to liquid- liquid 
extraction, providing an aqueous and an organic extract. The 
organic extract was fractionated into eight fractions using flash 
chromatography. Compounds 1-5 were isolated using mass 
guided semi- preparative HPLC and their structures elucidated 
using spectroscopic methods (HRMS, 1D- and 2D- MNR), as 
previously described.14
Antibacterial Screening and Chemical Investigation of  the 
Flash Fractions of  S. securifrons
The flash fractions of  the organic S. securifrons extract were 
assayed for activity against the pathogenic bacterial strains S. 
aureus, E. faecalis, E. coli, P. aeruginosa, and S. agalactiae (Gr. B) at 
250 µg/mL. Flash fraction three (eluting at 50% MeOH) was 
found to be active against the G+ bacterium s. agalactiae (Gr. B). 
Fraction three was inactive against the remaining bacteria and 
the remaining fractions were inactive against all bacteria. 
Chemical analysis of  the fraction using UHPLC- HRMS 
revealed that it contained compounds belonging to the secur-
amine family, including compounds 1, 2, 4, and 5.
Antimicrobial Activity of  1-5
The MIC values of  compounds 1-5 were determined against 
four G+ and two G- bacterial strains, three yeast strains and 
toward the biofilm formation capability of  S. epidermidis 
(Table 1, online supplementary file). Compounds 1, 2, and 5 
showed activity against all or most of  the G+ strains. No activ-
ity was found toward the G- bacteria, the yeast strains or 
against biofilm formation at the highest assay concentration 
(50 µM).
Figure 1. Structures of securamine C, E, and H – J (4, 5, and 1-3) isolated from the organic extract of the Arctic marine bryozoan Securiflustra 
securifrons.
Table 1. MIC (µM) of Securamine H- J, C, and E (1-5) Against four 
G+ and two G- Bacterial Strains, Against Staphylococcus epidermidis 
Biofilm Formation, and Against three Yeast Strains.
Microorganisms
Minimum inhibitory concentration (µM)
1 2 3 4 5
G+ bacteria:
Bacillus subtilis 6.25 >50 >50 >50 >50
Staphylococcus aureus 3.13 12.5 >50 >50 25
Enterococcus faecalis 6.25 25 >50 >50 50
Streptococcus agalactiae  
(Gr. B)
6.25 25 >50 >50 25
G- bacteria:
Escherichia coli >50 >50 >50 >50 >50
Pseudomonas aeruginosa >50 >50 >50 >50 >50
Biofilm formation:
Staphylococcus epidermidis >50 >50 >50 >50 >50
Yeast:
Candida albicans >50 >50 >50 >50 >50
Rhodotorula sp. >50 >50 >50 >50 >50
Aureobasidium pullulans >50 >50 >50 >50 >50
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Based on these results it appears that a double bond in the 
D- ring between C-2 and C-3 and more than one bromine on 
the A- ring at C-16, C-17, and/or C-18 are important for the 
antibacterial activity of  the securamines. This observed struc-
ture activity relationship (SAR) correlates well with the previ-
ously reported SAR of  the securamines against melanoma, 
lung and breast cancer cell lines,14 where 1, 2, 4, and 5 inhibited 
cell viability. The lowest MIC value, 3.13 µM, was measured for 
1 against S. aureus. Compound 1 is brominated at C-16, C-17, 
and C-18, and has a double bond between C-2 and C-3. This 
could indicate that the activities of  the securamines against 
both bacteria and cancer cell lines are caused by an unspecific 
interaction with and disruption of  biological membrane integ-
rity. This is, however, unlikely, as the herein assayed eukaryotic 
yeast strains were unaffected by the securamines at the highest 
assayed concentration (50 µM), indicating an unrelated intra-
cellular target in the cancer- and bacteria cells. Compound 1 
showed the broadest and most potent inhibition, with MIC 
values ranging from 3.13 to 6.25 µM against the G+ bacteria, 
and was, therefore, chosen for further investigation.
Real-Time Measurement of  Membrane Integrity of  Bacteria 
When Exposed to 1
B. subtilis and E. coli, carrying the pCSS962 plasmid with the 
LucGR gene, were used to assess the membrane disruptive 
properties of  1. The strains express eukaryotic luciferase and 
will emit luminescence if  their membrane is disrupted and 
D- luciferin from the growth medium is allowed to diffuse into 
the cell.19 If  the bacterial cells die following membrane disrup-
tion, an initial rise in relative luminescence units (RLU) caused 
by D- luciferin influx, will be followed by declining RLU values 
as bacterial ATP reserves are exhausted and the enzymatic 
reaction consequently stopped. The luminescence measure-
ments of  B. subtilis and E. coli after exposure to ranging concen-
trations of  1 or chlorhexidine (CHX, positive control), an 
antibiotic known for its cell wall and membrane- disruptive 
activities,20 can be seen in Figure 2. CHX treated B. subtilis gave 
an initial increase followed by a decrease in RLU values. In 
contrast to this, 1 caused a persistent increase in light emission 
from the cells within the 3 minutes assay time at the 3 hours 
highest concentrations tested (12.5, 25, and 50 µM; 2, 4, and 8 
× the MIC value of  6.25 µM, respectively). This increase was 
most likely caused by an increased D- luciferin influx into the 
cells caused by effects on the membrane. This effect does how-
ever not appear to affect the viability of  B. subtilis, as the ATP 
reserves in the bacteria are not exhausted and resultantly no 
delayed drop in RLU was observed, indicating that the effect 
of  1 was different from that of  CHX. The lack of  a drop in 
ATP reserves following B. subtilis exposure to 1 furthermore 
indicates that 1 is bacteriostatic rather than bactericidal at the 
highest assayed concentrations. At 6.25 µM (and at lower con-
centrations, data not shown) 1 did not cause an influx of  
D- luciferin, as relative light emission remained equal to the 
water control. In contrast to CHX, no substantial increase in 
D- luciferin uptake and thus no effect on plasma membrane 
integrity of  E. coli could be detected for 1, even at the highest 
assayed concentrations (Figure 2(B)).
Assessment of  the Membrane Potential of  Bacteria When 
Exposed to 1
To elucidate further if  1 affected the membrane integrity of  B. 
subtilis directly, the membrane potential of  B. subtilis was mea-
sured after 3 minutes exposure to ranging concentrations of  1. 
Bacterial cells were stained with a membrane potential sensitive 
dye and subsequently analyzed by flow cytometry. The assay is 
based on the use of  3,3’-diethylcarbocyanine iodide (DiOC2(3)), 
the fluorescence of  which shifts from green to red in response 
to higher cytosolic concentrations in cells with active mem-
brane potential where the dye aggregates. Ratiometric analysis 
of  green to red fluorescence allows for estimating changes in 
membrane potential of  bacteria.21 CHX and carbonyl cyanide 
m- chlorophenylhydrazone (CCCP) were used as positive and 
negative controls, respectively. CCCP blocks the generation of  
the electrochemical proton gradient, and thus lowers the 
Figure 2. Kinetics of the relative luminescence emission by A) B. subtilis (pCSS962) and B) E. coli (pCSS962) treated with ranging 
concentrations of either securamine H (1) or chlorhexidine (CHX). Each point is the mean of three independent measurements. CHX and 
water were used as positive and negative controls, respectively.
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membrane potential in bacteria.22 Increasing concentrations of  
CHX decreased the ratio of  red/green, showing that higher 
CHX concentrations result in a higher fraction of  bacteria with 
disrupted membranes. For 1, increased concentrations resulted 
in a decreased red/green ratio, but this decrease was signifi-
cantly less marked compared to the CCCP and CHX controls. 
At the observed MIC (6.25 µM), only a slight shift was visible, 
further indicating that the activity of  1 was not due to direct 
membrane integrity disruption (Figure 3).
Effect of  1 on Bacterial Metabolism
We proceeded to evaluate whether 1 affected bacterial metab-
olism. B. subtilis carrying a chromosomal integration of  a lux-
ABCDE23 operon and E. coli carrying the pCGLS-1124 plasmid 
with a Photorhabdus luminescens lux operon (luxCDABE) were 
used to assess the effect of  1 on bacterial cell viability mea-
sured in real- time. From these operons, the strains express a 
bacterial luciferase and fatty acid reductases for regeneration 
of  long- chain fatty aldehydes, which serve as substrates for 
light production. Light production is therefore linked to 
several metabolic processes, which in turn depend on the 
regeneration of  reduction equivalents and ATP.25,26 While 
light production indicates active metabolism, loss of  light pro-
duction indicates a decrease in metabolic activity, and hence, 
reduced viability of  the cells. The measured luminescence of  
B. subtilis and E. coli after addition of  ranging concentrations 
of  either 1 or CHX can be seen in Figure 4. At concentrations 
above the MIC (6.25 µM), 1 affected the viability of  B. subtilis 
within the 3 minutes assay time (Figure 4(A)). Indeed, 1 ele-
vated light emission by the strain at a similar level to CHX at 
3.1 µM, resulting in a decrease of  around 40% of  relative 
luminescence units after 3 minutes. The decrease in light emis-
sion within 3 minutes at concentrations above the MIC con-
firmed that cell viability was affected relatively fast. However, 
even at concentrations above the MIC, viability does not drop 
below 50%, which was the case for CHX. In addition, the 
ATP dependent membrane assay showed elevated light emis-
sion at these concentrations indicating that ATP levels are not 
the limiting factor. No effect was observed toward E. coli 
(Figure 4(B)).
Figure 3. The effect of securamine H (1) in comparison to chlorhexidine (CHX) on the membrane potential of B. subtilis. The bacteria were 
treated for 3 minutes with ranging concentrations of either 1 or CHX and subsequently incubated for at least 30 minutes with 30 µM DiSO2(3). 
The overlaid histograms show the positive and the negative controls treated with 5 µM carbonyl cyanide m- chlorophenylhydrazone (CCCP) 
(shaded dark grey) and water (shaded light grey), respectively. Measurements depicting analysis of 1 are highlighted. The ratiometric values 
(red/green) are depicted on the x axis, and the relative number of events on the y axis.
Figure 4. Kinetics of the relative luminescence emission by A) B. subtilis (pCGLS-11) and B) E. coli (pCGLS-11) treated with ranging 
concentrations of either securamine H (1) or chlorhexidine (CHX).
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In summary, the results from the membrane integrity and 
metabolic activity assays show an influx of  D- luciferin at con-
centrations higher than the MIC, no effect on membrane 
potential, and reduction of  metabolic activity in B. subtilis 
exposed to 1. The effect of  1 on B. subtilis viability is thus most 
likely not caused by direct effects on the cell membrane, but 
rather by interference with one or more metabolic processes in 
B. subtilis.
Investigation of  Possible Intracellular Targets of  1
In an attempt to gather information regarding the mode of  
action of  1, the compound was tested against a panel of  six 
biosensors responding to interference with some major meta-
bolic pathways in B. subtilis. Compound 1 was tested for inter-
ference with DNA replication, transcription, translation and 
interference with fatty acid, cell wall and folic acid synthesis. 
Antibiotics of  the respective modes of  action, as shown in 
Table 2, served as positive controls. None of  the strains reacted 
to co- incubation with 1 at the assayed concentrations during 
the 8 hours the assays were run (twofold dilution series between 
50 and 0.39 µM). The purpose of  the sensors is to detect simi-
lar activity, but negative results do not exclude a given mode of  
action. While, for example, erythromycin efficiently induces 
the sensor for translation interference, kanamycin does not.27 
Similarly, the cell envelope stress sensor, which is based on the 
liaI promoter and the liaRS two- component system, is most 
sensitive when challenged with antibiotics affecting the lipid II 
cycle, as is the case for bacitracin and vancomycin, while they 
remain uninduced by penicillin.28 This hampers the interpreta-
tion of  the results since all the assays for the activity of  1 were 
negative. However, 1 seems not to belong to the subgroups of  
antibiotic mode of  actions that the sensors recognize. 
Interestingly, the liaI based cell envelope stress sensor is known 
to respond to membrane active compounds such as nisin.28 
Therefore, the negative response to 1 was in accordance with 
earlier results indicating a different mode of  action than inter-
ference with membrane integrity.
Conclusions
Securamine H (1) was found to inhibit the viability of  G+ bac-
teria and to reduce metabolic activity in B. subtilis. The effect 
was shown not to be caused by interference with DNA replica-
tion, transcription, or translation, nor by interference with fatty 
acid, cell wall and folic acid synthesis, and could not be 
explained by disruption of  the cell membrane. The mode of  
action of  1 thus remains to be deconvoluted. However, as the 
result indicates that 1 has an intracellular target, the compound 
serves as an interesting starting point for further investigations. 
The herein presented results demonstrate that marine bryozo-
ans can be used as a source of  compounds with antibacterial 
activity.
Experimental
Animal Material, Extraction, Fractionation, Compound 
Isolation, and Structure Elucidation
Specimens of  S. securifrons were collected off  the coast of  
Hjelmsøya, Norway in 2014 using an Agassi’s dredge trawl at 
72  m depth. The specimens were prepared as an organic 
extract, which was further fractionated into eight fractions 
using RP- flash chromatography and tested for bioactivity. The 
compounds were isolated using mass- guided semi- preparative 
HPLC and their structure elucidated using spectroscopic meth-
ods (HRMS, 1D- and 2D- NMR), all as previously described in 
detail.14
Microorganism Strains, Growth Media, and Assay 
Temperature
Enterococcus faecalis (ATCC: 29212) and Streptococcus agalactiae (Gr. 
B) (ATCC: 12386) were grown and assayed in brain- heart infu-
sion broth (BHI; Oxoid, Hampshire, England). Staphylococcus 
aureus (ATCC: 25923), Escherichia coli (ATCC: 25922), 
Pseudomonas aeruginosa (ATCC: 27853), and Bacillus subtilis 
(ATCC: 23857) and its derivatives were grown and assayed in 
Mueller Hinton Broth (MH; Merck, Darmstad, Germany). 
Staphylococcus epidermidis (ATCC: 35984) was grown and assayed 
in tryptic soy broth (TS; Merck, Darmstadt, Germany). All 
bacteria were grown and assayed at 37 °C. The yeast strains 
Candida albicans (ATCC: 10231) and Rhodotorula sp. and the 
Aureobasidium pollulans mold (Rhodotorula sp and A. pollulans 
were obtained from Professor Arne Tronsmo, the Norwegian 
College of  Life Sciences, Ås, Norway), were cultivated and 
assayed on potato dextrose agar (PD, Difco, Detroit, MI, USA) 
with 2% D(+)- glucose (Merck, Darmstad, Germany) at room 
temperature.
Antimicrobial and Anti Biofilm Formation Assays
Antibacterial assay. MIC values of  1-5 were determined using 
the broth microdilution method, as previously described.15 
Briefly, suspended bacteria in log phase were added to 96- well 
Table 2. List of Sensor Strains With the Promoter Region Fused to 
the luxABCDE Operon Located in the sacA Region of the B. subtilis 
168 Chromosome. Respective Positive Control Antibiotics Used Are 
Shown in the Last Column.
Strain number Target Promoter Control antibiotic
EM10 DNA replication yorB Ciprofloxacin
EM11 Transcription helD Rifampicin
EM12 Translation yheI Erythromycin
HMB67 Wall and membrane liaI Vancomycin/Bacitracin
HMB69 Fatty acid synthesis fabHB Triclosan/Irgasan
HMB70 Folic acid synthesis panB Trimethoprim
HMB62 Viability control laiG all
Natural Product Communications6
microtiter plates at a concentration of  1,500‐15,000 colony 
forming units/mL. Serial dilutions of  1-5 (assay cons: 50‐0.78 
µM) were subsequently added and left to inoculate for 24 hours 
before growth inhibition was measured using a Victor multi-
label counter (Perkin Elmer, Singapore) at 600 nm. Growth 
medium diluted with water (1:1) was used as negative control 
and bacteria suspension diluted with water (1:1) as positive 
control. For B. subtilis, oxytetracycline was used as the positive 
assay control, and for the remaining strains, gentamycin was 
used. The assays were repeated three times.
Inhibition of  biofilm formation. S. epidermidis was used to assess 
the effect of  1-5 on biofilm formation. An overnight culture of  
S. epidermidis was diluted with fresh TS broth with 1% glucose 
(1:100), transferred to the wells of  96- well microtiter plates, 
and ranging concentrations (assay cons: 50‐0.39 µM) of  1-5 
were added. After overnight incubation, the bacterial suspen-
sion was carefully discarded, the biofilm fixed by incubation 
at 55 °C for 1 hour and stained with 0.1% crystal violet for 
5 minutes before being washed away with water. The plates 
were once more left to dry at 55 °C for 1 hour before 70 µL 
70% ethanol was added to each well and the plates left to incu-
bate for 10 minutes before biofilm formation was observed by 
visual inspection of  the plates. The MIC was defined as the 
lowest concentration where no biofilm formation was visible. 
S. epidermidis suspension, diluted with 50 µL of  water, was used 
as a positive control, and 50 µL Staphylococcus haemolyticus sus-
pension with 50 µL of  water as negative control. A mixture of  
50 µL water and 50 µL TS broth was used as assay control. The 
assay was repeated three times.
Antifungal assay. Fungal spores of  yeast strains Candida albicans 
and Rhodotorula sp. and the A. pollulans mold were added to 
PD broth and the cell concentration determined and adjusted 
after counting in a Bürker chamber. A final fungal spore con-
centration of  2 × 105 spores/mL was inoculated in 96- well 
Nunc microtiter plates (100 µL total well volume) along with 
ranging concentrations of  1-5 (assay cons: 50‐0.78 µM). The 
assay plates were incubated at room temperature for either 24 
hours (C. albicans) or 48 hours (A. pollulans and Rhodotorula sp.). 
Ranging concentrations of  amphotericin- B was used as posi-
tive control (32-0.25 µg/mL), and water as a negative (growth) 
control. After incubation, the OD value (600 nm) was mea-
sured in a Synergy H1 Hybrid Reader (BioTek, Winooski, VT, 
USA). MIC values of  1-5 were defined as the lowest concen-
tration of  the compounds that showed >90% inhibition com-
pared to the negative growth control (as measured by OD). 
The assays were repeated three times.
Mode of  Action Studies
Real-time membrane integrity assay measuring immediate membrane 
disruption. The real- time membrane integrity assay was per-
formed using B. subtilis 168 and E. coli K12 (MC1061), both 
carrying the plasmid pCSS962 with the eukaryotic luciferase 
gene lucGR. Luciferase is dependent on D- luciferin as sub-
strate to emit light, a substrate that does not penetrate intact 
cell membranes. The assay is a modification of  a previously 
described protocol.19 B. subtilis and E. coli were cultured over-
night in MH broth with 5 µg/mL chloramphenicol (Merck 
KGaA, Darmstad, Germany) and a mixture of  20 µg/mL 
chloramphenicol/100 µg/mL ampicillin, respectively, before 
being centrifuged at 4500 rpm for 10 minutes. The supernatant 
was removed and the pellet resuspended in MH broth to give 
an OD600 of  0.1. D- luciferin potassium salt (assay concentra-
tion: 1 mM) was added and background luminescence mea-
sured. Ranging concentrations of  1 (assay conc.: 50‐0.78 µM) 
dissolved in water were added to black round- bottom 96- well 
microtiter plates (Nunc, Roskilde, Denmark), as well as a rang-
ing concentrations of  the control, CHX acetate (assay conc.: 50 
µM-1.6 µM). The plates were placed in a Synergy H1 Hybrid 
Reader (BioTek, Winooski, VT, USA). Aliquots (90 µL, to give 
a total assay volume of  100 µL) of  the prepared bacterial sus-
pension were added to the test wells by an automatic injector 
with tracking of  the luminescence emission every second for 
180 s. The assays were repeated 3 times.
Membrane potential assay. To analyze the effects of  1 on the 
membrane potential of  Bacillus subtilis 168, the BacLight bac-
terial membrane potential kit (Invitrogen, Carlsbad, CA, 
USA) was used. The assays were performed in 96 well 1.8 ml 
deepwell- plates (Corning, Corning, NY, USA) and analyzed by 
a Cube8 flow cytometer with an auto sampler (Sysmex, Kobe, 
Japan). The assay is based on the dye DiOC2(3), which causes 
green fluorescence in all bacterial cells. The fluorescence shifts 
to red when the dye molecules self- associate due to their accu-
mulation in the cytoplasm of  viable bacteria with intact mem-
brane potential.21 Differences in fluorescence emission were 
detected by flow cytometry. The ratiometric values of  red/
green fluorescence were used to analyze if  the proton gradi-
ent of  the tested cells was affected or not. The experiment 
was performed according to the manufacturer’s suggestions, 
but adapted to the 96 well format and therefore conducted 
with reduced volumes. Briefly, 5 µl 3 mM DiOC2(3) solution 
was added to 500 µl cell suspension, which contained approx-
imately 106 bacteria and had been pretreated for 3 minutes 
with different concentrations of  the respective analytes. Before 
starting the measurement, the samples were incubated in the 
dark for 30 minutes at room temperature. The samples were 
then measured in the Cube8 and analyzed with excitation 
by the blue laser (488 nm) and forwards scatter (FSC), side 
scatter (SSC), FL1 (emission 536/40 nm) and FL3 (emission 
675/20 nm). Data analysis was performed by the freely avail-
able flowing software using the first 2000 events of  the bacte-
rial population in each measurement for ratiometric analysis 
( flowingsoftware. btk. fi).
Real-time cell viability assay. The real- time cell viability assay was 
performed using B. subtilis 168 (ATCC: 23857) and E. coli K12 
(ATCC: MC1061) carrying either a chromosomal integration of  
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the luxABCDE operon or the plasmid pCGLS-11 with the lux 
operon luxCDABE, respectively. The assay is a modification of  a 
previously described protocol.29 B subtilis and E. coli were cultured 
overnight in MH broth with 5 µg/mL chloramphenicol and 100 
µg/mL ampicillin (Merck KGaA, Darmstad, Germany), respec-
tively, before being centrifuged at 4500 rpm for 10 minutes. The 
supernatant was removed and the pellet resuspended in MH broth 
to give an OD600 of  0.1. Ranging concentrations of  1 (assay conc.: 
50‐0.78 µM) dissolved in water were added to black round- bottom 
96- well microtiter plates (Nunc, Roskilde, Denmark), as well as 
ranging concentrations of  the control, CHX acetate (assay conc.: 
50 µM – 1.6 µM). The plates were placed in a Synergy H1 Hybrid 
Reader (BioTek, Winooski, VT, USA). Aliquots (90 µL, to give a 
total assay volume of  100 µL) of  the prepared bacterial suspension 
were added to the test wells by an automatic injector with tracking 
of  the luminescence emission every second for 180 s. The assays 
were repeated three times.
Promotor activity-based whole-cell biosensor assay. Whole cell mode of  
action, specific biosensors were used to determine if  the activity 
of  1 correlates with some previously known modes of  actions. 
The biosensors were generated by cloning promoter fusions to 
luxABCDE in the plasmid pBS3Clux and subsequent recombina-
tion into the sacA site on the B. subtilis chromosome, as described.23 
Interference with DNA replication, transcription, translation and 
fatty acid synthesis was tested by B. subtilis strains containing 
luxABCDE fusions to the promotors of  the genes yorB, helD, 
yheI and fabHB, respectively, as described for firefly luciferase.27 
Inhibition of  cell wall synthesis was tested by a bacitracin induc-
ible promoter construct described23 based on the promotor of  
liaI fused to luxABCDE. The veg promoter fusion described in 
the same paper was used as a luminescence control. In addition, 
a panB- luxABCDE promoter fusion described as a lacZ- fusion in 
patent US20020164602A130 was used to test for inhibition of  folic 
acid synthesis (details in Table 2). Compound 1 was tested in a 
two- fold dilution series starting with two x B. subtilis MIC (MIC 
= 6.25 µM). The respective control antibiotics were set up similar 
to the tested compound. The experiments were run at room tem-
perature. Otherwise, the identical setup to the antimicrobial assay 
protocol was used with additional measurement of  luminescence 
every 15 minutes for 8 hours. Peak luminescence of  the controls 
was compared to luminescence of  cells treated with 1. The assays 
were repeated three times.
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